I-MAB (IMAB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
I-Mab, a U.S.-based global biotech firm focusing on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP as its independent auditor for fiscal year 2024. This move is part of I-Mab’s strategic shift to reinforce its presence as a U.S. biotech entity, with no reported issues from the previous auditor. The company leaders express confidence in PwC’s alignment with shareholder interests and the firm’s capabilities to support I-Mab’s long-term growth objectives.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
